Effect Of Once-Weekly Semaglutide on Weight Change and Metabolic Control in People with Type 1 Diabetes-Six-Months Results from the Real-World STEMT Trial

被引：0
|
作者：
Mertens, Jonathan
de Winter, Hennah T.
Mazlom, Hadi
Peiffer, Frida W.
Dirinck, Eveline L.
Bochanen, Niels
Van Gaal, Luc F.
de Block, Christophe
机构：
来源：
DIABETES | 2022年 / 71卷
关键词：
D O I：
10.2337/db22-751-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
751-P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Once-weekly semaglutide use in glucagon-like peptide-1 receptor agonist naive patients with type 2 diabetes in North Macedonia: Real-world data from the MIRAGE study
    Milenkovikj, Tatjana
    Mitreva, Biljana Chekorova
    Mishevska, Sasha Jovanovska
    Bitoska-Mileva, Iskra
    Ahmeti, Irfan
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 206
  • [32] Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: A randomized, placebo-controlled, double-blind, crossover trial
    Korsatko, Stefan
    Jensen, Lene
    Brunner, Martina
    Sach-Friedl, Stefanie
    Tarp, Maja D.
    Holst, Anders G.
    Heller, Simon R.
    Pieber, Thomas R.
    DIABETES OBESITY & METABOLISM, 2018, 20 (11): : 2565 - 2573
  • [33] Real-World Assessment of Switching from a Dipeptidyl Peptidase-4 Inhibitor to Exenatide Once-Weekly in Patients with Type 2 Diabetes
    Gorgojo-Martinez, Juan J.
    Gargallo-Fernandez, Manuel A.
    Brito-Sanfiel, Miguel A.
    Lisbona-Catalan, Arturo
    DIABETES, 2017, 66 : A297 - A297
  • [34] Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (PAUSE)
    James Amamoo
    Riddhi Doshi
    Joshua Noone
    Lin Xie
    Cory Gamble
    Mico Guevarra
    Victoria Divino
    Justin Chen
    Aaron King
    Diabetes Therapy, 2025, 16 (5) : 1033 - 1048
  • [35] Effects of Once-Weekly Semaglutide on Cardiovascular Risk Factors and Metabolic Dysfunction-Associated Steatotic Liver Disease in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study Based on Real-World Data
    Katsuyama, Hisayuki
    Hakoshima, Mariko
    Kaji, Emika
    Mino, Masaaki
    Kakazu, Eiji
    Iida, Sakura
    Adachi, Hiroki
    Kanto, Tatsuya
    Yanai, Hidekatsu
    BIOMEDICINES, 2024, 12 (05)
  • [36] Real-world HbA1c changes and prescription characteristics among type 2 diabetes mellitus patients initiating treatment with once weekly semaglutide for diabetes
    Frazer, Monica
    Swift, Caroline
    Sargent, Andrew
    Leszko, Michael
    Buysman, Erin
    Gronroos, Noelle N.
    Alvarez, Sara
    Dunn, Tyler J.
    Noone, Josh
    Gamble, Cory L.
    JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2024, 23 (01) : 783 - 788
  • [37] Glucagon-like peptide-1 receptor agonist-experienced adults with type 2 diabetes switching to once-weekly semaglutide: post hoc analysis of the real-world SURE programme
    Rudofsky, G.
    Menzen, M.
    Potier, L.
    Catarig, A. -M.
    Clark, A.
    Priyadarshini, P.
    Abreu, C.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S334 - S335
  • [38] Persistence and Adherence of Once-Weekly GLP-1 Receptor Agonists in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease in a Real-World Setting
    Dunn, Tyler
    Zhu, Yong
    Gronroos, Noelle
    Xie, Lin
    Noone, Joshua
    Sargent, Andrew
    Yedigarova, Larisa
    Billings, Liana K.
    DIABETES, 2024, 73
  • [39] Glycemic control of once-weekly and other administration frequencies for DPP-4 inhibitor in patients with type 2 diabetes: a real-world retrospective cohort study
    Koto, Ruriko
    Yoshida, Shiori
    Nakajima, Akihiro
    Miwa, Tetsuya
    Nishimura, Rimei
    DIABETOLOGY INTERNATIONAL, 2024, 15 (03) : 632 - 637
  • [40] Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis
    Rudofsky, Gottfried
    Menzen, Markus
    Potier, Louis
    Catarig, Andrei-Mircea
    Clark, Alice
    Priyadarshini, Prachi
    Abreu, Cristina
    ADVANCES IN THERAPY, 2025, 42 (02) : 788 - 800
12345